Stock Research for ALKS

ALKS

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ALKS Stock Chart & Research Data

The ALKS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALKS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ALKS Due diligence Resources & Stock Charts

The ALKS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ALKS Detailed Price Forecast - CNN Money CNN View ALKS Detailed Summary - Google Finance
Yahoo View ALKS Detailed Summary - Yahoo! Finance Zacks View ALKS Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ALKS Trends & Analysis - Trade-Ideas Barrons View ALKS Major Holders - Barrons
NASDAQ View ALKS Call Transcripts - NASDAQ Seeking View ALKS Breaking News & Analysis - Seeking Alpha
Spotlight View ALKS Annual Report - CompanySpotlight.com OTC Report View ALKS OTC Short Report - OTCShortReport.com
TradeKing View ALKS Fundamentals - TradeKing Charts View ALKS SEC Filings - Bar Chart
WSJ View Historical Prices for ALKS - The WSJ Morningstar View Performance/Total Return for ALKS - Morningstar
MarketWatch View the Analyst Estimates for ALKS - MarketWatch CNBC View the Earnings History for ALKS - CNBC
StockMarketWatch View the ALKS Earnings - StockMarketWatch MacroAxis View ALKS Buy or Sell Recommendations - MacroAxis
Bullish View the ALKS Bullish Patterns - American Bulls Short Pains View ALKS Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ALKS Stock Mentions - StockTwits PennyStocks View ALKS Stock Mentions - PennyStockTweets
Twitter View ALKS Stock Mentions - Twitter Invest Hub View ALKS Investment Forum News - Investor Hub
Yahoo View ALKS Stock Mentions - Yahoo! Message Board Seeking Alpha View ALKS Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ALKS - SECform4.com Insider Cow View Insider Transactions for ALKS - Insider Cow
CNBC View ALKS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ALKS - OTC Markets
Yahoo View Insider Transactions for ALKS - Yahoo! Finance NASDAQ View Institutional Holdings for ALKS - NASDAQ


Stock Charts

FinViz View ALKS Stock Insight & Charts - FinViz.com StockCharts View ALKS Investment Charts - StockCharts.com
BarChart View ALKS Stock Overview & Charts - BarChart Trading View View ALKS User Generated Charts - Trading View




Latest Financial News for ALKS


SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alkermes plc – ALKS
Posted on Wednesday January 16, 2019

NEW YORK, NY / ACCESSWIRE / January 16, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Alkermes plc (''Alkermes'' or the ''Company'') (ALKS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Alkermes and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.


IMPORTANT DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Posted on Wednesday January 16, 2019

LOS ANGELES, CA / ACCESSWIRE / January 16, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc ("Alkermes" or "the Company") (NASDAQ: ALKS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The FDA issued a briefing document about Alkermes' new drug application for ALKS 5461 on October 30, 2018, in advance of an FDA advisory committee meeting about the drug.


SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline: February 25, 2019
Posted on Wednesday January 16, 2019

NEW YORK, NY / ACCESSWIRE / January 16, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Alkermes plc, Inc.("Alkermes" or the "Company") (NASDAQ: ALKS) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Alkermes securities between February 17, 2017 and November 1, 2018, inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.


Alkermes Announces Recipients of 1st Annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program
Posted on Wednesday January 16, 2019

DUBLIN, Jan. 16, 2019 /PRNewswire/ -- Alkermes plc (ALKS) today announced the recipients of the ALKERMES PATHWAYS RESEARCH AWARDSSM program, designed to support the next generation of researchers working on the front lines to advance understanding and awareness of central nervous system (CNS) disorders. In its inaugural year, the Pathways program will provide an aggregate of $400,000 in grants to junior investigators who have demonstrated their commitment to helping those living with substance use disorders (SUD), including those associated with the use of opioids and alcohol. "An estimated one-in-seven people in the U.S. will develop a substance use disorder in their lifetime1, which is why we urgently need to accelerate research efforts focused on improving prevention, treatment and awareness of this public health crisis," said Craig Hopkinson, M.D., Chief Medical Officer and Senior Vice President of Medicines Development and Medical Affairs at Alkermes.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.